SciSparc Gets FDA Nod for Tourette Syndrome Phase IIb Trial
Ticker: SPRC · Form: 6-K · Filed: Sep 23, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, FDA-approval, biotech
TL;DR
SciSparc just got FDA green light for a Phase IIb Tourette's trial. Big step!
AI Summary
On September 23, 2024, SciSparc Ltd. announced it received FDA approval to begin a Phase IIb clinical trial for its Tourette Syndrome treatment. This trial will evaluate the safety and efficacy of SciSparc's drug candidate, SCI-110, in patients with Tourette Syndrome.
Why It Matters
FDA approval for a Phase IIb trial is a significant step in drug development, indicating the treatment shows promise and moving SciSparc closer to potentially offering a new therapy for Tourette Syndrome.
Risk Assessment
Risk Level: medium — Clinical trial progression carries inherent risks, and FDA approval for a trial does not guarantee eventual market approval or commercial success.
Key Players & Entities
- SciSparc Ltd. (company) — The company filing the report and receiving FDA approval.
- FDA (company) — The regulatory body that granted approval for the clinical trial.
- September 23, 2024 (date) — The date the press release announcing the FDA approval was issued.
- SCI-110 (drug_candidate) — SciSparc's drug candidate to be tested in the Phase IIb trial.
FAQ
What is the specific indication for the Phase IIb clinical trial?
The Phase IIb clinical trial is for the treatment of Tourette Syndrome.
What is the name of SciSparc's drug candidate being tested?
The drug candidate being tested is named SCI-110.
On what date was the press release regarding the FDA approval issued?
The press release was issued on September 23, 2024.
What type of clinical trial has SciSparc received approval to initiate?
SciSparc has received approval to initiate a Phase IIb clinical trial.
Which regulatory body granted SciSparc approval for this trial?
The U.S. Food and Drug Administration (FDA) granted SciSparc approval for this trial.
Filing Stats: 317 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2024-09-23 09:10:19
Filing Documents
- ea0215363-6k_scisparc.htm (6-K) — 12KB
- ea021536302ex99-1_scisparc.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-080824.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: September 23, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3